Clinical anaerobic infections

Anaerobe

Volumn 5, Issue 3-4, 1999, Pages 347-350

  Goldstein, Ellie J C ^a,b,c  

^a Santa Monica UCLA Medical Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Anaerobic infection

Indexed keywords

BETA LACTAMASE INHIBITOR; CARBAPENEM; CLINAFLOXACIN; GEMIFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ABSCESS; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL INFECTION; CONFERENCE PAPER; GASTROINTESTINAL INFECTION; HUMAN; MORBIDITY; MORTALITY; MOUTH INFECTION; MOUTH MUCOSA; MUCOSA; ODOR; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 0033141235     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1006/anae.1999.0271     Document Type: Conference Paper

References (32)

1. Finegold S. M., George W. L. Anaerobic Infections in Humans. 1989;Academic Press, San Diego.
2. Finegold S. M. Review of early research on anaerobes. Clin Infect Dis. 18:1994;S248-249.
3. Tanner A., Maiden M. F., Lee K., Shulman L. B., Weber H. P. Dental implant infections. Clin Infect Dis. 25:1997;S213-S217.
4. Nachnani S., Clark G. T. Halitosis: a breath of fresh air. Clin Infect Dis. 25:1997;S218-219.
5. Brook I., Fraser E. H., Foote P. A. Microbiology of the transition from acute to chronic maxillary sinusitis. J Med Microbiol. 45:1996;372-375.
6. Goldstein E. J.C. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol. 47:1998;1-3.
7. Goldstein E. J., Citron D. M., Wield B., Blachman U., Sutter V. L., Miller T. A., Finegold S. M. Bacteriology of human and animal bite wounds. J Clin Microbiol. 8:1978;667-672.
8. Bartlett J. G., O'Keefe P., Tally F. P., Louie T. J., Gorbach S. L. Bacteriology of hospital-acquired pneumonia. Arch Intern Med. 146:1986;868-871.
9. Bennion R. S., Baron E. J., Thompson J. E., Downes J., Summanen P., Talan D. A., Finegold S. M. The bacteriology of gangrenous and perforated appendicitis-revisited. Ann Surg. 211:1990;165-171.
10. Christou N. V., Turgeon P., Wassef R., Rotstein O., Bohnen J., Potvin. Management of intra-abdominal infections: the case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg. 131:1996;1193-2001.
11. Browder W., Smith J. W., Vivoda L. M., Nichols R. L. Nonperforative appendicitis: a continuing surgical dilemma. J Infect Dis. 159:1989;1088-1094.
12. Ferzoco L. B., Raptoulos V., Silen W. Acute diverticulitis. N Engl J Med. 338:1998;1521-1526.
13. Goldstein E. J.C. Anaerobic bacteremia. Clin Infect Dis. 23:1996;97-101.
14. Periano V. A., Cross S. A., Goldstein E. J.C. Incidence and significance of anaerobic bacteremia in community hospital. Clin Infect Dis. 16:1993;S288-S291.
15. Brook I. Anaerobic bacterial bacteremia: 12-year experience in two military hospitals. J Infect Dis. 160:1989;1071-1075.
16. Rendondo M. C., Arbo M. D.J., Grindlinger J., Snydman D. R. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis. 20:1995;1492-1496.
17. Kato N., Kato H., Watanabe K., Uneo K. Association of enteroxtoxogenic Bacteroides fragilis with bacteremia. Clin Infect Dis. 23:1996;S83-86.
18. Nord, C. E. Third Annual Anaerobe Society of the Americas Congress on Anaerobic Infections, Buenos Aires, 25 April 1998.
19. Malnick H., Williams K., Phil-Eboise J., Levy A. S. Description of a medium for isolating Anaerobiospirillum spp., a possible cause of zoonotic disease from diarrheal feces and blood of human and use of the medium in a survey of human, canine, and feline feces. J Clin Microbiol. 28:1990;1380-1384.
20. Malnick H. Anaerobiospirillum thomasii sp. nov., an anaerobic spiral bacterium isolated from the feces of cats and dogs and from diarrheal feces of humans, and emendation of the genus Anaerobiospirillum. Int J Syst Bacteriol. 47:1997;381-384.
21. Myers L. L., Shoop D. S., Newman R. J. Isolation of enterotoxogenic Bacteroides fragilis from humans with diarrhea. J Clin Microbiol. 25:1987;2330-2333.
22. San Joaquin V. H., Griffis J. C., Christopher L., Sears C. L. Association of Bacteroides fragilis with childhood diarrhea. Scand J Infect Dis. 27:1995;211-215.
23. Moss S. E., Klein R., Klien B. E.K. The prevalence and incidence of lower extremity amputation in diabetic population. Arch Intern Med. 152:1992;610-616.
24. Sapico F. L., Whitte J. N., Canawati H. N., Montgomery J. Z., Bessman A. N. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis. 6:1984;S171-176.
25. Goldstein E. J.C., Citron D. M., Goldman R. J., Claros M. C., Hunt-Gerardo S. United States hospital survey of anaerobic culture and susceptibility methods II. Anaerobe. 1:1995;309-314.
26. Goldstein E. J.C., Citron D. M., Goldman R. National hospital survey of anaerobic culture and susceptiblity methods: results and recommendations for improvement. J Clin Microbiol. 30:1992;1529-1534.
27. Goldstein E. J.C. Efficacy and safety of new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859) in the treatment of anaerobic infections. Clin Infect Dis. 23:1996;S25-30.
28. Snydman D. R., McDermott L. Analysis of the in vitro activity of trovafloxacin (CP-99, 219) against Bacteroides species. Inf Dis Clin Pract. 5:1996;S96-100.
29. Stein G. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis. 23:1996;S19-24.
30. Citron D. M., Appleman M. D. Comparative in vitro activities of trovafloxacin (CP-99, 219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother. 41:1997;2312-2316.
31. Cormican M. G., Jones R. N. Antimicrobial activity and spectrum of LB 20304, a novel fluoronapthyridone. Antimicrob Agents Chemother. 41:1997;204-211.
32. Goldstein E. J.C., Citron D. M., Hudspeth M., Gerardo S. H., Merriam C. V. In vitro activity of Bay 12-8039, a new 8-methoxy quinolone, compared to 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother. 41:1997;1552-1557.